Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 84Neoplasm Metastasis 8Neoplasms 6Sarcoma 4Squamous Cell Carcinoma of Head and Neck 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Head and Neck Neoplasms 2Colonic Neoplasms 2Carcinoma, Squamous Cell 2Wilms Tumor 1Urinary Bladder Neoplasms 1Untreated Operable Early Breast Cancer 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Teratoma 1Somatostatinoma 1Solid Tumors 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrent Squamous Cell Lung Carcinoma 1Rectal Neoplasms 1

Interventions

Temozolomide 66Radiotherapy 34Carboplatin 22Carmustine 21Bevacizumab 21Irinotecan 18Filgrastim 18Surgical Procedures, Operative 14Vincristine 11Peripheral Blood Stem Cell Transplantation 11Etoposide 11Radiation 10O(6)-benzylguanine 10Magnetic Resonance Spectroscopy 9Lomustine 9Procarbazine 8Erlotinib Hydrochloride 8sargramostim 7IL13-PE38 7Everolimus 7Cyclophosphamide 7Chemotherapy, Adjuvant 7Thiotepa 6Radiotherapy, Intensity-Modulated 6Imatinib Mesylate 6Granulocyte Colony-Stimulating Factor 6Drug Therapy 6Cisplatin 6temsirolimus 5antineoplaston AS 2-1 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Astrocytoma × palbociclib × Clear all
NCT02530320 2024-11-22

Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved

Grupo Español de Investigación en Neurooncología

Phase 2 Completed
34 enrolled 13 charts
CNS

Astrocytoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡